Cullinan Oncology Ownership

CGEM Stock  USD 8.52  0.20  2.29%   
The majority of Cullinan Oncology LLC outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Cullinan Oncology LLC to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Cullinan Oncology. Please pay attention to any change in the institutional holdings of Cullinan Oncology LLC as this could imply that something significant has changed or is about to change at the company.
 
Shares in Circulation  
First Issued
2020-03-31
Previous Quarter
58 M
Current Value
54 M
Avarage Shares Outstanding
40.5 M
Quarterly Volatility
11.6 M
 
Covid
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cullinan Oncology LLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

Cullinan Stock Ownership Analysis

About 95.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.84. Some equities with similar Price to Book (P/B) outperform the market in the long run. Cullinan Oncology LLC recorded a loss per share of 2.78. The entity had not issued any dividends in recent years. The firm had 2:1 split on the 31st of August 2009. Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. Cullinan Management operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 31 people. For more info on Cullinan Oncology LLC please contact Nadim Ahmed at 617 410 4650 or go to https://cullinantherapeutics.com.
Besides selling stocks to institutional investors, Cullinan Oncology also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Cullinan Oncology's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Cullinan Oncology's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.

Cullinan Oncology Quarterly Liabilities And Stockholders Equity

621.82 Million

Cullinan Oncology Insider Trades History

About 5.0% of Cullinan Oncology LLC are currently held by insiders. Unlike Cullinan Oncology's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Cullinan Oncology's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Cullinan Oncology's insider trades
 
Covid

Cullinan Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Cullinan Oncology is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cullinan Oncology LLC backward and forwards among themselves. Cullinan Oncology's institutional investor refers to the entity that pools money to purchase Cullinan Oncology's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Rtw Investments, Llc2024-12-31
1.7 M
Vr Adviser, Llc2024-12-31
1.4 M
Dimensional Fund Advisors, Inc.2024-12-31
1.3 M
Kynam Capital Management, Lp2024-12-31
1.3 M
Geode Capital Management, Llc2024-12-31
1.2 M
Siren, L.l.c.2024-12-31
1.2 M
Braidwell Lp2024-12-31
1.2 M
Nextech Invest Ag2024-12-31
1.1 M
Adage Capital Partners Gp Llc2024-12-31
M
Mpm Oncology Impact Management Lp2024-12-31
7.6 M
Bvf Inc2024-12-31
5.8 M
Note, although Cullinan Oncology's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Cullinan Oncology LLC Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cullinan Oncology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cullinan Oncology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cullinan Oncology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Jennifer Michaelson over a week ago
Acquisition by Jennifer Michaelson of 50000 shares of Cullinan Oncology at 4.3 subject to Rule 16b-3
 
Sumer Jacquelyn L over three weeks ago
Disposition of 3756 shares by Sumer Jacquelyn L of Cullinan Oncology at 8.53 subject to Rule 16b-3
 
Mary Fenton over a month ago
Acquisition by Mary Fenton of 60000 shares of Cullinan Oncology subject to Rule 16b-3
 
Jennifer Michaelson over two months ago
Disposition of 4000 shares by Jennifer Michaelson of Cullinan Oncology at 12.51 subject to Rule 16b-3
 
Nadim Ahmed over two months ago
Disposition of 8400 shares by Nadim Ahmed of Cullinan Oncology at 11.87 subject to Rule 16b-3
 
Sumer Jacquelyn L over three months ago
Disposition of 3482 shares by Sumer Jacquelyn L of Cullinan Oncology at 11.41 subject to Rule 16b-3
 
Jennifer Michaelson over six months ago
Disposition of 8000 shares by Jennifer Michaelson of Cullinan Oncology at 18.09 subject to Rule 16b-3
 
Jeffrey Trigilio over six months ago
Disposition of 319 shares by Jeffrey Trigilio of Cullinan Oncology at 13.11 subject to Rule 16b-3
 
Jennifer Michaelson over six months ago
Disposition of 176 shares by Jennifer Michaelson of Cullinan Oncology at 13.11 subject to Rule 16b-3
 
Nadim Ahmed over six months ago
Disposition of 4272 shares by Nadim Ahmed of Cullinan Oncology at 9.24 subject to Rule 16b-3
 
Jennifer Michaelson over six months ago
Disposition of 11900 shares by Jennifer Michaelson of Cullinan Oncology at 12.31 subject to Rule 16b-3
 
Jennifer Michaelson over six months ago
Disposition of 8000 shares by Jennifer Michaelson of Cullinan Oncology at 16.33 subject to Rule 16b-3

Cullinan Oncology Outstanding Bonds

Cullinan Oncology issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Cullinan Oncology LLC uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Cullinan bonds can be classified according to their maturity, which is the date when Cullinan Oncology LLC has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Cullinan Oncology Corporate Filings

8K
27th of February 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F4
21st of February 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
13A
14th of November 2024
An amended filing to the original Schedule 13G
ViewVerify
13A
8th of November 2024
The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934
ViewVerify

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Cullinan Oncology LLC is a strong investment it is important to analyze Cullinan Oncology's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cullinan Oncology's future performance. For an informed investment choice regarding Cullinan Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cullinan Oncology LLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.
You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cullinan Oncology. If investors know Cullinan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cullinan Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.78)
Return On Assets
(0.22)
Return On Equity
(0.32)
The market value of Cullinan Oncology LLC is measured differently than its book value, which is the value of Cullinan that is recorded on the company's balance sheet. Investors also form their own opinion of Cullinan Oncology's value that differs from its market value or its book value, called intrinsic value, which is Cullinan Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cullinan Oncology's market value can be influenced by many factors that don't directly affect Cullinan Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cullinan Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cullinan Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cullinan Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.